Background

There are many medicinal products that, although having shown efficacy and safety in different ophthalmological indication, they are not authorized or commercially available for ophthalmic administration.

Purpose

To evaluate the elaborations of ophthalmological medicines which must be prepared in the Pharmacy Service.

Material and methods

Retrospective study of ophthalmological preparations in a reference hospital.

January 2016 ← December 2017

<table>
<thead>
<tr>
<th>Parameters</th>
<th>2016</th>
<th>2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total ophthalmological preparations</td>
<td>17188</td>
<td>20430</td>
</tr>
<tr>
<td>Eye drops</td>
<td>13990</td>
<td>16838</td>
</tr>
<tr>
<td>Intraocular injections</td>
<td>3128</td>
<td>3592</td>
</tr>
</tbody>
</table>

The main increase was concentrated in saving of aflibercept 2mg/0.05ml intraocular injections.

Eye drops

- Autologous serum 20%
- Autologous serum 50%
- Cyclosporine 0.05%
- Vancomycin 5%
- Ceftazidime 5%
- Others

The main increase was concentrated in saving of aflibercept 2mg/0.05ml intraocular injections.

Intraocular injections

- Cefuroxime 1mg/0.1ml
- Aflibercept 2mg/0.05ml
- Vancomycin 1mg/0.1ml
- Ceftazidime 2mg/0.1ml
- Bevacizumab 5mg/0.2ml
- Others

The main increase was concentrated in saving of aflibercept 2mg/0.05ml intraocular injections.

Results

Eye drops

- Bevacizumab 2.5% eye drops ($12,008.4/\text{year}$)
- 98% of the total expense ($260,920€$

Intravitreal syringes of aflibercept 2mg / 0.05ml ($244,920€/\text{year}$)

Conclusion

The ophthalmological preparations in pharmacy hospital have increased 19%. Autologous serum 20% and cyclosporine 0.05% were impacted of 92% eye drops, including the longest storage duration tested. They must be prepared in the Pharmacy Service according to quality criteria to ensure its effectiveness, stability and sterility and supposed a high economic impact ($260,816.76€$)

References